Dana-Farber Research News 06.15.2026 - Takeaways - MDSpire

Dana-Farber Research News 06.15.2026

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from May 16 - 31.

  • By

  • June 15, 2026

  • 27 min

Share

  • 1

    Dana-Farber's newsletter highlights research by faculty published from May 16-31, 2026.

  • 2

    The TAC01-HER2 trial showed manageable toxicity and early efficacy in patients with HER2-positive advanced solid tumors.

  • 3

    The CROWN study reported that lorlatinib demonstrated unprecedented long-term progression-free survival in advanced ALK-positive NSCLC.

  • 4

    The POSITIVE trial confirmed that temporary interruption of endocrine therapy for pregnancy is safe in young women with hormone receptor-positive breast cancer.

  • 5

    Longer follow-up in the POSITIVE trial indicated no increased risk of breast cancer events with fertility preservation strategies.

Original Source(s)

Dana-Farber Research News 06.15.2026

  • by

  • June 15, 2026

Related Content

Endovascular thrombectomy in selected patients with active cancer and thrombocytopenia: outcomes under an institutional platelet transfusion practice

A screening model for advanced colorectal neoplasia based on tumor markers and inflammatory indices: a retrospective study with an online risk calculator

Oncolytic virotherapy counteracts the selection of IFN-unresponsive cancer cells post-immunotherapy but is limited by the emergence of dedifferentiated cancer cells